Previous studies of propofol (2,6-diisopropylphenol) pharmacology have shown that this widely used anaesthetic drug is extensively cleared from the body by conjugation of the parent molecule or its quinol metabolite. On the basis of potential influence of propofol on the metabolism of co-administered agents, many investigators have evaluated the effects of propofol on cytochrome P450 (CYP) activities. CYP isoforms involved in propofol metabolism are not defined. In this study, our objective was to elucidate further the CYP isoforms responsible for the hydroxylation of propofol. Using microsomes from 12 different human livers, we investigated CYP isoforms involved in propofol hydroxylase activity, using selective chemical inhibitors of CYP isoforms, correlation with immunoquantified specific CYP isoform content, immunoinhibition, and 11 functionally active human CYP isoforms expressed in a heterologous system (yeast and human B-lymphoblastoid cells). We found a low variability in the production of the hydroxylated metabolite of propofol, 2,6-diisopropyl-1,4-quinol. This activity was mediated by CYP and followed Michaelis-Menten kinetics with apparent K M and V max values of 18 M (95% CI 15.1-20.1) and 2.6 nmol min 91 mg 91 (95% CI 2.45-2.68) respectively. Part of the propofol hydroxylase activity was mediated by CYP2C9 in human liver, especially at low substrate concentration. Moreover, propofol was likely to be metabolized by additional isoforms such as CYP2A6, 2C8, 2C18, 2C19 and 1A2, especially when substrate concentrations are high. This low specificity among CYP isoforms may contribute to the low interindividual variability (two-fold) and may contribute to the low level of metabolic drug interactions observed with propofol. (Br.
Propofol (2,6-diisopropylphenol) is one of a series of substituted phenols with highly lipophilic properties resulting in a wide distribution. 1 Propofol is used for its short-lasting anaesthetic action, which results from rapid decay of its plasma concentrations. 1 2 In humans propofol is eliminated from the body only after being metabolized, because less than 0.3% of the dose is excreted from the body as the parent compound and most of the drug (73%) is eliminated as water-soluble conjugates via the kidneys on the first day. 1 3 4 In human beings, the major metabolite is the glucuronic acid conjugate of propofol, which accounts for 53-73% of the total metabolites, depending principally on the administered dose of propofol. 1 4 The importance of this metabolic pathway is also species-dependent. 3 5 The other metabolites recovered in human urine are the two glucuronic acid (conjugation at the C1 or C4 position) and the sulphate conjugates (conjugation at the C4 position) of the ring-hydroxylated derivative of propofol, 2,6-diisopropyl-1,4-quinol (1,4-quinol) . 1 4 These minor metabolites need a preliminary hydroxylation at the C4 position. Consequently, hydroxylation of the parent compound accounts for a maximum of 47% of the total dose of propofol. 1 4 All these metabolic pathways reduce or suppress the activity of propofol. Glucuronidation at the 1 or 4 position or sulphation at the 4 position suppress the activity of the compound while the 1,4-quinol has about one-third the hypnotic activity of propofol. 3 This important metabolic clearance to pharmacologically inactive derivatives, associated with a rapid initial distribution phase, limit the effect of propofol and contribute to the excellent recovery from anaesthesia observed in patients. 6 The total body clearance of propofol is rapid, and as propofol is eliminated only by metabolism, the liver would be expected to be the organ predominantly responsible for the clearance of propofol, 7 8 even if extrahepatic sites such as the kidneys 8 or lungs 9 10 are also involved in propofol glucuronidation.
Previous investigations have shown that propofol decreased animal 11 or human 12 cytochrome P450 (CYP) activities in vitro. It has been shown that propofol interacts with the haem moiety of the haemoprotein in the CYP enzyme. 13 The variable inhibition observed in CYP-mediated activities may be attributable to the differential binding of propofol to CYP isoforms. 13 Even if hydroxylation of propofol on its phenol ring is not the major metabolic pathway, 1 4 14 the involvement of the CYP-dependent mono-oxygenases in this biotransformation could be the basis of metabolic interactions, 12 15 or of a genetic polymorphism that could explain the particular metabolic profile observed in a patient who exhibited a high conjugation pathway of propofol and a slight ring-hydroxylation. 4 The purpose of the present study was to characterize the isoform(s) of CYP metabolizing propofol. Identification of the major CYP isoform responsible for propofol hydroxylation in humans may aid a better understanding of the inhibitory effects of propofol on CYP-mediated activities.
Materials and methods

DRUGS AND CHEMICALS
Propofol and 2,6-diisopropyl-1-4 quinol were obtained from Zeneca Pharma (Cergy, France). Midazolam was supplied by Roche (Neuilly sur Seine, France). Coumarin, sulphaphenazole, quinidine, diethyldithiocarbamate, troleandomycin, 7-8 benzoflavone, glucose-6-phosphate (G6P), glucose-6-phosphate dehydrogenase (G6PDH), and nicotinamide adenine dinucleotide phosphate (NADP + ) were purchased from Sigma (St Quentin Fallavier, France). All sodium dodecyl sulphate-polyacrylamide gel electrophoresis reagents were obtained from Bio-Rad (Paris, France). Other chemicals were of the highest grade commercially available.
HUMAN LIVER MICROSOMES
Experiments with human tissue were approved by the local ethics committee. Fresh human liver samples were obtained from Caucasian patients who underwent partial hepatectomy. Morphologically normal fragments were collected on the material removed in excess and were prepared as reported previously. 16 Less than 10 min elapsed from removal of liver to collecting and freezing a sample in liquid nitrogen. Patients with acute or chronic hepatitis and with cirrhosis were excluded from the study. In correlation studies, 12 different human liver samples (HL1 to HL12) were used.
PREPARATION OF MICROSOMAL FRACTIONS
Microsomes from human livers were prepared by differential centrifugation as described previously. 17 Microsomal fractions were aliquoted in small volumes and stored at 980ЊC in potassium phosphate buffer (200 mM, pH 7.4) containing 1mM EDTA and glycerol (20%, v/v) before use.
Total CYP content was measured using the method developed by Omura and Sato. 18 Microsomal proteins were assessed according to a modification of Lowry's method using bovine serum albumin as standard.
DETERMINATIONS OF ENZYMATIC ACTIVITIES
Reaction rates were verified to be linear as a function of incubation time and protein concentrations under the conditions described below. In a final volume of 1 ml, a typical reaction mixture contained phosphate buffer (100 mM, pH 7.4 or Tris-HC1 buffer 50 mM pH 7.4 for incubations performed with microsomes from human lymphoblastoïd cells) containing an NADPH-generating system composed of NADP + (0.5 mM), G6P (5 mM), and G6PDH (1.6 unit), 0.5-0.7 mg of microsomal protein, and 10-50 M propofol. The substrate was prepared daily in methanol and diluted in water (1:100, v/v) before being introduced into the reaction mixture (0.02% methanol final concentration). Reactions were performed at 37 ЊC for 7-10 min; they were started by adding substrate and stopped by adding 50 l sodium hydroxide (1 mol l
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). Total propofol metabolism by liver microsomes was determined as the amount of 2,6-diisopropyl-1,4-quinol produced (1,4-quinol) . Propofol and 2,6-diisopropyl-1,4-quinone (transformed under alkaline conditions from 1,4-quinol) in incubation mixtures were determined by using a gas chromatography-mass spectrometry assay used in our laboratory. 20 Briefly, propofol, its metabolite, and thymol used as an internal standard were extracted in chloroform/ethyl acetate (70:30, v/v). After centrifugation, 1 of the organic layer was injected into the capillary column (HP5: 30 m 0.25 mm i.d. 0.25 m film thickness). Propofol, 2,6-diisopropyl-1,4-quinone and thymol were detected by selected ion monitoring at mass/charge ratios of 163 (propofol), 149 (2,6-diisopropyl-1,4-quinone) and 135 (thymol). Identification of the metabolite, 1,4-quinol, was based on co-elution and comparison of the mass spectrum with the authentic standard. Precision and accuracy were below 10% (within-run) and below 16% (between-run) at low concentrations. The limit of detection of 1,4-quinol was 25 ng ml 91 . Coumarin 7-hydroxylase and 7 ethoxycoumarin O-deethylase activities at a substrate concentration of 100 M were determined fluorometrically as described by Aitio and colleagues. 21 Tolbutamide hydroxylase activity was determined on four different human microsomes. Microsomal incubations with 1 mM tolbutamide (methanol) and 2 mg protein were assessed in a final volume of 1 ml for 1 h at 37ЊC. Extraction and quantification of hydroxytolbutamide were assayed according to Relling and colleagues with minor modifications. 22 The effect of substrate concentration on the rate of production of 1,4-quinol was evaluated with a concentration of propofol from 2 M to 200 M from three different microsomal fractions. All assays were performed in duplicate or triplicate. Effective chemical inhibitors were used as probes of specific CYP isoforms involved in the metabolism of propofol. Inhibitors were introduced into the incubation medium simultaneously with the substrate except for troleandomycin and orphenadrine; these were preincubated with microsomes and the NADPHgenerating system at 37ЊC for 20 min to produce sufficient reactive metabolites, which led to specific inhibition. The reaction was then continued with substrate for an additional 10 min. Inhibitors used as probes of specific CYP-mediated activities were diethyldithiocarbamate (100 M; CYP2E1), sulphaphenazole (50 M; CYP2C9), quinidine (10 M; CYP2D6), midazolam (100 M; CYP3A4), troleandomycine (100 M; CYP3A4), 7-8 benzoflavone (10 M; CY7P1A1), coumarin (100 M; CYP2A6) and orphenadrine (50 M; CYP2B6), which are known to suppress more than 80% of the activities mediated by the CYP isoform given in parentheses. 23 Clotrimazole (50 M) and n-octylamine (1 mM) were also used for their low specificity in inhibiting CYP-mediated activities. Specific immunoinhibitions were also performed, using purified rabbit polyclonal immunoglobulins (IgG) directed against rat NADPHcytochrome P450 reductase. Rat liver NADPHcytochrome P450 reductase was purified using the method described by Yasukoshi and Masters. 24 Immunological inhibition studies were assayed using 0.2 mg of microsomal protein preincubated with 10 mg of purified IgG for 30 min at 37ЊC. The NADPHcytochrome P450 reductase activity was evaluated according to the method described by Masters and colleagues. 25 Purified IgG anti-rat NADPHcytochrome P450 reductase was shown to inhibit 80% Figure 2 Relationships between microsomal CYP3A4, CYP2D6, CYP1A2, CYP2E1, CYP2C8, CYP2C9 immunoreactive content and the rate of formation of 2,6-diisopropyl-1,4-quinol by 12 different human liver microsome preparations. Each data point represents the mean of triplicate determinations from each human liver and is expressed in arbritrary units (percent of the fraction expressing the highest immunoreactivity). Statistical analysis was performed using a stepwise multiple regression.
of the cytochrome c reductase activity in human liver micosomes. Immunoinhibition against CYP2C9-dependent activity was also performed using serum from primary immunized rabbits by CYP2C9 obtained from yeast expressing the corresponding cDNA. Experimental conditions for immunoinhibition were identical. For each inhibited activity, control experiments were conducted under the same conditions with the same amount of methanol needed for solubilization of the inhibitor (1% final concentration) or with serum obtained from standard rabbits.
WESTERN BLOT ANALYSIS
Human hepatic microsomal fractions (2-100 g protein) were subjected to immunoblotting as described previously, 26 using rabbit immunoglobulins against the main human CYP isoforms (that is, CYP1A2, 2C8, 2C9, 2D6, 2E1 and 3A4). The intensity of the bands was determined by laser densitometry using a densitometer (Scan Jet 2C, Hewlett Packard) linked to a microcomputer running Scan Analysis software. Various concentrations of liver microsomes were loaded on each gel to establish a standard curve. The amount of each CYP isoform was expressed in arbitrary units and compared with the specific content of the corresponding CYP isoform of the human liver fraction exhibiting the highest activity.
CDNA-EXPRESSED CYP ISOFORMS
Incubations with CYP expressed in recombinant yeast were also performed to assess the involvement of specific CYP isoforms in the production of 1,4-quinol. Transformed yeast were produced and microsomes were prepared as previously described. 27 Incubations were performed in a final volume of 1 ml (28ЊC, 30 min) containing yeast expressing one of the following human CYP isoforms (CYP1A1, 1A2, 2C8, 2C9, 2C18, 2C19, 2D6, 2E1, 3A4 or 3A5: 200 pmol), cytochrome b 5 (200 pmol), 10 and 50 M propofol, in a NADPH-regenerating system containing 10 mM MgC1 2 . Microsomes from human lymphoblast cells expressing, CYP2A6 (Gentest, Woburn, MA, USA) were also used under conditions recommended by the manufacturer (37ЊC, 30 min in Tris-HC1 buffer 50 mM, pH 7.4).
The relationship between Western blot (or coumarin 7-hydroxylase activity) versus 1,4-quinol formation was calculated using a step-wise multiple regression performed in StatView software (Abaccus Concepts Inc., Berkeley, CA, USA), accepting P: 0.05 as significant. Statistical significance in inhibition studies was assessed using Student's t test with P :0.05. Kinetic parameters (propofol concentration from 2 to 200 M) were obtained by non-linear least squares regression. The minimum values of the sum of the squared residuals were computed using NAG Fundation Library routine E04FDF (Numerical Algorithms Group Ltd, The Math Works Inc., Natick, MA, USA).
Results
PROPOFOL HYDROXYLASE ACTIVITY
Human liver microsomes exhibited propofol hydroxylase activity (0.89 (0.20) nmol min 91 mg
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) and 1,4-quinol was the only metabolite recovered. The mass spectrum of the metabolite peak was identical to that of authentic 1,4-quinol (data not shown). No other possible metabolite could be found in either the GC-MS system with or without silylation or in an HPLC system with UV detection. Furthermore, assays of propofol metabolism by measurement of the formation of 1,4-quinol or by measurement of propofol disappearance gave similar results. The interindividual variation in the rate of formation of the 1,4-quinol in the 12 different samples was no more than two-fold (0.66-1.30 nmol min 91 mg
). Incubations performed without an NADPHgenerating system, or in the presence of clotrimazole, n-octylamine, or IgG anti-rat NADPH-cytochrome P450 reductase decreased the formation of 1,4-quinol by more than 80%. The conversion of propofol was linear over the protein concentration range 0.5-3 mg ml 91 and 0.2-1 mg ml
, for up to 20 min for 50 M and 10 M of propofol respectively. The propofol hydroxylase activity assayed with different concentrations of the substrate (2- fig. 1 .
INVESTIGATIONS OF HUMAN LIVER CYP INVOLVED IN PROPOFOL HYDROXYLASE ACTIVITY
To characterize the involvement of liver-specific CYP in the metabolism of propofol, the rate of formation of 1,4-quinol by human microsomes was compared with their specific content of CYP isoforms ( fig. 2) . A stepwise multiple regression was performed to take into account the contribution of different CYP isoforms in propofol metabolism. Activities of all microsomal fractions obtained with a substrate concentration of 10 M exhibited a significant correlation (r:0.78, P:0.0076) with the microsomal immunoquantified-content of CYP2C9. None of the other immunochemically-tested human CYP isoforms (that is, CYP1A2, 2C8, 2D6, 2E1, and 3A4) Figure 3 Correlation between the 7-OH coumarin hydroxylase activity and the formation of 2,6-diisopropyl-1,4-quinol by human liver microsomes. Each value is the mean of two separate assays.
could be related to the specific activity of each microsome. Similarly, there was no significant correlation between the rate of formation of 1,4-quinol and the coumarin 7-hydroxylase activity (r:0.42, fig. 3 ), a marker of CYP2A6-mediated activities, or total CYP content. When incubations were assessed with a higher concentration of propofol (50 M), correlation between the rate of formation and CYP2C9 was not significant (r: 0.51). Heterologous systems expressing 11 different CYP isoforms were used to assess the intrinsic ability of these isoforms to catalyse propofol. Results are shown in table 1. Microsomes from yeast expressing CYP2C9 exhibited a high activity for formation of 1,4-quinol. Lymphoblast cells expressing CYP2A6 were also reasonably active. Other cDNAs of CYP expressed in yeast (that is, CYP1A1, 2C8, 2C18, 2C19, or 1A2) produced the 1,4-quinol, at low concentration of substrate (10 M). With an increase in the substrate concentration (50 M), other isoforms hydroxylated propofol but the activities remained negligible. These concentration are commonly observed in plasma after a single bolus for induction of anaesthesia, 2 28 although the actual intracellular concentration around the active sites is uncertain. Enzymatic efficency (V max /K M ) of several isoforms was also determined (table 1), CYP2C9 exhibiting the highest rate.
Selective chemical CYP inhibitors were also used in this study to determine the potential roles of CYP isoforms in the metabolism of propofol (table 2) . A moderate inhibition (around 25%) was observed in incubations performed, with a 10 M concentration of propofol, with sulphaphenazole as a competitive inhibitor of CYP2C9 despite a broad inhibition of the tolbutamide hydroxylase activity under the same conditions. The percentage inhibition diminished when the concentration of the substrate was set at 50 M. Similar inhibitions were found with coumarin (21%) or orphenadrine. No other agent tested significantly inhibited propofol hydroxylase activity.
Immunoinhibition assessed with IgG anti-CYP2C9, ranging from 25 to 75 l of immune serum, exhibited a decrease in activity from 3.7% to 46.7% respectively (values are the mean of three assays performed separately in microsomes from three samples selected for their high response in immunoblot performed with anti-CYP2C9).
Discussion
In human microsomal fractions, 1,4-quinol was the single hydroxylated metabolite of propofol recovered. In vivo studies showed the presence of sulphate or glucuronide conjugates of propofol or of its hydroxylated metabolite: 1,4-quinol.
1 4 1,4-quinol is the only identified hydroxylated metabolite of propofol and could represent as much as 47% of the total metabolism of propofol over 1 day. 1 4 Absence of an NADPH-generating system, or co-incubations with clotrimazole, n-octylamine or IgG anti-reductase from rat dramatically decrease the production of the 1,4-quinol indicating the activity of CYP in propofol metabolism. These results are complementary with 
HL3 10  --23  ----0  50  -15  10  8  --17  -HL4  10  --19  -----HL5  10  --39  ----13  50  9  12  1  29  25  0  9  8  HL7  10  --25  ----5  50  -15  7  25  --11  -HL11  10  --21  ----- those previously reported by Chen and colleagues, who observed that propofol competed with carbon monoxide for a common binding site on the haem moiety. 13 Propofol hydroxylation follows MichaelisMenten kinetics and is consistent with the existence of a single active site or different catalytic sites with close affinities, because the existence of two or more CYP with similar affinities for propofol would not be distinguished in the kinetic studies. The K M value is near physiological plasma concentrations. 2 29 The present study clearly demonstrates the involvement of CYP2C9 in the metabolism of propofol. This conclusion is supported by several lines of evidence. A significant correlation between immunochemically determined CYP and the hydroxylation of propofol was confirmed only for CYP2C9 at a concentration (10 M) near the value of the Michaelis-Menten constant. Similarly, immunoinhibition and CYP2C9 expressed in yeast confirm the participation of this isoform in the production of the 1,4-quinol, despite a weak inhibition of the activity in fractions coincubated with sulphaphenazole, a chemical inhibitor of CYP2C9-catalysed activities. 30 Although sulphaphenazole is an efficient inhibitor of reactions mediated by CYP2C9 with Ki values from 0.12 to 0.3 M on tolbutamide hydroxylation, 30 31 it was unable to inhibit more than 39% of the production of 1,4-quinol. Nevertheless, some studies suggest the possible involvement of isoforms other than CYP2C9 in the metabolism of propofol. First, the linear regression of the relationship between the immunochemical reactivity of CYP2C9 and the production of 1,4-quinol has a y-intercept significantly different from zero (46% of residual activity compared with the mean of the activity). Second, immunological and chemical inhibitions decrease propofol hydroxylase activity, which remains below 50% of the control activity. Finally, correlation between the propofol hydroxylase activity determined with a substrate concentration of 50 M and immunochemical-CYP2C9 reactivity was not significant despite a two-fold increase in this activity (data not shown). These data suggest the participation of several isoforms, which should account for the remaining activity at therapeutic concentrations. Microsomes prepared from cells containing various CYP isoforms were used to support these arguments. Thus, microsomes from cells expressing CYP2A6 or 1A1 raised to a high propofol hydroxylase activity even at low substrate concentrations as well as several isoforms (that is, 2C8, 2C18, 2C19, 1A2) that exhibited a lower activity and a low enzymatic efficiency. These heterologous systems provide evidence on the intrinsic capacity of a specific isoform to catalyze the reaction 32 33 and strongly suggest in vivo participation if the expression level in organs or tissues involved in the metabolic pathways of the drug, or the concentration of the drug around the active site, or both, are sufficient. 34 Nevertheless, the involvement of these isoforms in metabolic pathways may be overestimated. Thus, when we focus on the effective involvement of these isoforms in microsomal fractions, all results are inconclusive. This may be the consequence of a low expression of these specific isoforms in the microsomal fractions (for example, CYP1A1 is usually expressed in liver at very low level, CYP2A6 accounts for about 4% of total CYP) or a narrow range of levels of some CYP isoforms in our liver bank (especially 2A6, 3A4).
Many investigators have studied the possible interaction between propofol and other anaesthetic drugs such as alfentanil and derivatives 12 13 15 35 or enflurane 11 because these compounds are often associated in anaesthetic procedures. Previous studies in humans did not show any pharmacokinetic interactions between propofol and fentanyl 36 or propofol and alfentanil. 35 However, Janicki and colleagues showed a decrease in the in vitro oxidative metabolism of alfentanil and sufentanil by propofol. 12 The metabolic transformation of these opioids is primarily mediated by CYP3A4. 37 38 Furthermore, the present study shows a low participation of 3A4 even at high concentrations of propofol. Nevertheless, these data do not rule out a possible interaction between propofol and this isoform that might explain the interaction observed by Janicki and colleagues. In contrast, other authors showed, in rabbits, that pretreatment with cimetidine, an inhibitor of CYP3A4-mediated activities, 39 did not affect the in vitro rate of propofol elimination. 9 Our study also clearly shows that CYP2E1 is not involved in propofol metabolism at low substrate concentration as was previously observed in rats by Baker and colleagues. 11 Nevertheless, some authors have observed an in vitro concentration-dependent inhibitory effect of propofol on CYP2E1-mediated activities in hamster and in human. 13 15 These discrepancies may also be explained by the difference in the substrate concentration, because inhibition studies in human microsomes were performed with 0.5 and 1 mM, concentrations that are not clinically relevant. 13 In the same way, earlier in vivo studies showed that the plasma concentrations of propofol were higher in patients pretreated with fentanyl. 6 It seems that this kind of interaction may be related to an inhibition of the two compounds on the glucuronidation pathways 8 rather than to a direct interaction on CYP. In vitro inhibition by propofol of the glucuronidation of propranolol has already been observed. 40 41 Nevertheless, the rarity of the interactions occurring between clinically used drugs and propofol may be explained by other events. First, glucuronidation which is a major pathway of the metabolism of propofol may be catalysed by different isoforms of UDP-glucuronosyltransferases and the latter are known to exhibit a broad specificity towards a large number of compounds. 8 42 43 Secondly, the hepatic extraction coefficient for propofol is very high.
In conclusion, CYP2C9 is involved, by at least 50%, in the oxidative metabolism of propofol, particularly at low substrate concentration. Other isoforms, such as CYP2A6, 2C8, 2C18, 2C19 and 1A2, are also involved in this metabolism but the characterization of their relative activities remains difficult. It can be postulated that the increase in propofol concentration or the defect of CYP2C9 contributes to the participation of this CYPs, or promotes the glucuronidation, a pathway known to be of low specificity and high capacity. 8 From the clinical point of view, the contribution of multiple isoforms in a metabolic pathway of a highly metabolized therapeutic agent might be desirable because its metabolism is not affected by polymorphism and is less affected by metabolic interactions with other drugs, except in individuals expressing a high proportion of one of these isoforms.
